Synchrony Financial (NYSE:SYF – Get Rating) announced its quarterly earnings results on Monday. The financial services provider reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.14, RTT News reports. The business had revenue of $4.74 billion during the quarter, compared to analyst estimates of $4.04 billion. Synchrony Financial had a return on equity of 24.07% and a net margin of 17.51%. During the same period in the previous year, the company earned $1.48 EPS.
Synchrony Financial Stock Performance
Shares of SYF stock traded up $0.18 during trading hours on Wednesday, reaching $35.55. 330,928 shares of the company’s stock were exchanged, compared to its average volume of 6,727,527. Synchrony Financial has a fifty-two week low of $27.22 and a fifty-two week high of $47.05. The company has a quick ratio of 1.21, a current ratio of 1.20 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $16.02 billion, a P/E ratio of 5.60, a P/E/G ratio of 0.98 and a beta of 1.61. The business has a fifty day moving average price of $34.25 and a 200-day moving average price of $33.43.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on SYF shares. Credit Suisse Group cut their price objective on shares of Synchrony Financial from $38.00 to $37.00 and set an “outperform” rating on the stock in a research report on Tuesday. StockNews.com lowered shares of Synchrony Financial from a “buy” rating to a “hold” rating in a research note on Thursday, October 20th. BMO Capital Markets lowered their target price on shares of Synchrony Financial from $56.00 to $53.00 and set an “outperform” rating on the stock in a research report on Tuesday. JPMorgan Chase & Co. reduced their price target on Synchrony Financial from $39.00 to $36.00 in a research report on Tuesday, January 10th. Finally, Citigroup upped their price target on Synchrony Financial from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $39.27.
Institutional Trading of Synchrony Financial
Institutional investors have recently modified their holdings of the company. First Trust Advisors LP raised its stake in shares of Synchrony Financial by 853.5% in the first quarter. First Trust Advisors LP now owns 6,218,641 shares of the financial services provider’s stock valued at $216,471,000 after purchasing an additional 5,566,481 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Synchrony Financial in the 1st quarter valued at $61,172,000. Goldman Sachs Group Inc. lifted its holdings in shares of Synchrony Financial by 6.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,123,671 shares of the financial services provider’s stock worth $282,786,000 after acquiring an additional 484,220 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Synchrony Financial by 45.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 550,851 shares of the financial services provider’s stock worth $19,175,000 after acquiring an additional 171,755 shares during the period. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Synchrony Financial during the 1st quarter valued at about $4,950,000. Institutional investors and hedge funds own 95.97% of the company’s stock.
Synchrony Financial Company Profile
Synchrony Financial engages in the provision of consumer financial services. It operates through three sales platforms: Retail Card, Payment Solutions, and CareCredit. The Retail Card platform is a provider of private label credit cards, and also provides Dual Cards and small-and medium-sized business credit products.
- Get a free copy of the StockNews.com research report on Synchrony Financial (SYF)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Synchrony Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synchrony Financial and related companies with MarketBeat.com's FREE daily email newsletter.